Company news

Immunovant, Inc. news in 2024

Immunovant, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024

November 6, 2024

Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves’ Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting

October 28, 2024

Ankyra Announces Appointment of Dr. Julia Butchko and Ms. Tara Withington to the Board of Directors

September 22, 2024

Roivant Provides Update on Graves’ Disease Development Program

September 8, 2024

Immunovant Provides Update on Graves’ Disease Development Program

September 8, 2024

Immunovant to Host Graves’ Disease Program Update on September 9, 2024

September 4, 2024

Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2024

August 5, 2024

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024

May 28, 2024

Immunovant Awarded U.S. Patent for IMVT-1402

March 11, 2024

Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended December 31, 2023

February 11, 2024

Immunovant to Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 2, 2024

Decks in 2024